Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 Whitehawk Therapeutics (Nasdaq: WHWK) will present three preclinical abstracts at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026. Presentations cover ADC programs HWK-016 (oral minisymposium), HWK-007 (poster) and HWK-206 (poster).Preclinical highlights include tumor regressions at low single-digit mg/kg doses, a highest non-severely toxic dose (HNSTD) of 60 mg/kg in non-human primates, and low circulating free payload tied to a proprietary carbon-bridge cysteine repairing linker-payload.

#WHWK Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

www.stocktitan.net/news/WHWK/whitehawk-ther...

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights Whitehawk Therapeutics (Nasdaq: WHWK) reported Q4 and full-year 2025 results and development updates on March 12, 2026. Key points: $145.7M cash and short-term investments at year-end, active Phase 1 recruitment for HWK-007 and HWK-016, and a planned IND submission for HWK-206 in mid-2026 with Phase 1 start targeted for Q3 2026.Full-year net loss was $20.6M (includes an $87.3M gain from the AADI divestiture); Q4 net loss was $23.3M. Preclinical data presentation expected spring 2026; initial Phase 1 results expected in 1H 2027.

#WHWK Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

www.stocktitan.net/news/WHWK/whitehawk-ther...

Leading Indicators, Thursday January 8, 2026 – Crystal Equity Research

Small-cap stocks in new uptrend with ave directional index, Thu Jan 8th - #SCHL #UCTT #VRA #WHWK #XBIT #EGGF #FLYX #GPUS #SACH #STXS #ALLO #BAER #CRML #FRPL #KLXE #MBUU #OTGA #POWI #RCAT #WKC #VAC #SCM #RES #OIS #HUYA #FPI #DDD #BHR - More: crystalequityresearch.com/leading-indi... - #smallcap

#WHWK Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

www.stocktitan.net/news/WHWK/whitehawk-ther...

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC Whitehawk Therapeutics (Nasdaq: WHWK) presented a large real-world RNA analysis of PTK7 at AACR‑NCI‑EORTC on Oct 24, 2025. The study evaluated >157,000 tumor samples and found PTK7 expressed in ~70% of solid tumors, ranking PTK7 as the third most highly expressed ADC target after HER2 and HER3. Highest median PTK7 mRNA levels were reported in endometrial (7.4), ovarian (7.2), head and neck (7.1), NSCLC (6.9) and breast (6.7).Expression was stable across histologic subtypes, disease stage and metastatic status. Whitehawk plans an IND filing for HWK‑007 (a PTK7‑directed ADC with a TOPO1 payload) by year‑end, targeting initial trials in NSCLC, ovarian and endometrial cancers.

#WHWK Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC

www.stocktitan.net/news/WHWK/whitehawk-ther...

Most Searched, Thursday October 16, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Oct 16th - #TMQ #NAK #ABAT #DVLT #VERI #SES #MVST #WHWK #SLNH #NVTS #HIVE #SLNH #RXRX #USAR #TGB #PCSA #METC #LAC #DPRO #AUUD - More: crystalequityresearch.com/most-searche... - #smallcap

Trade Alerts, Thursday October 16, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Thu Oct 16th - #WHWK #WATT #SOND #REE #PRAX #KCHV #DTIL #CBIO #BMRA #ANY - More: crystalequityresearch.com/trade-alerts... - #smallcap

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research Tempus (NASDAQ: TEM) announced a multi-year collaboration with Whitehawk Therapeutics (NASDAQ: WHWK) to use Tempus’ de-identified multimodal real-world dataset and AI platform to advance biomarker-driven oncology research.The agreement will support Whitehawk’s clinical trial design and indication prioritization for its antibody drug conjugate (ADC) portfolio targeting PTK7, MUC16, and SEZ6, with a focus on cancers such as lung and gynecological indications. The partnership will evaluate concordance between RNA and IHC expression to explore RNA testing as an objective, reproducible, scalable alternative for patient identification.Date announced: October 16, 2025.

#TEM #WHWK Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

www.stocktitan.net/news/TEM/tempus-announce...

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights MORRISTOWN, N.J., Aug. 7, 2025/ PRNewswire/-- Whitehawk Therapeutics, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the second quarter ended June 30, 2025, and provided recent corporate progress.

#WHWK Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

www.stocktitan.net/news/WHWK/whitehawk-ther...

NEWS: ( NASDAQ: #WHWK ) Expected earnings - Whitehawk Therapeutics Inc.

Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights Whitehawk Therapeutics (NASDAQ: WHWK) reported Q1 2025 financial results and corporate updates. The company has relaunched as an ADC-focused oncology therapeutics company with three assets targeting PTK7, MUC16, and SEZ6. Key financial highlights include cash position of $231.1M as of March 31, 2025, up from $47.2M in December 2024, supported by a $100M PIPE financing and the $102.4M divestiture of Aadi Subsidiary to Kaken Pharmaceuticals. Q1 2025 saw revenue of $7.1M from FYARRO sales and net income of $73M, including an $87.4M gain from the Aadi sale. The company expects its current cash position of approximately $185M to fund operations into 2028 and remains on track to file its first IND in Q4 2025, with all three assets targeted for IND submission by mid-2026.

#WHWK Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights

www.stocktitan.net/news/WHWK/whitehawk-repo...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Mon May 5th- #CATO #SQNS #UFI #FLGC #HRTX #SDST #WHWK #NTCL #PITX #NXL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Major Transformation: Aadi Becomes Whitehawk with $180M War Chest for ADC Cancer Programs Whitehawk emerges with three WuXi-licensed ADC assets targeting lung and ovarian cancers, backed by $170M cash runway through 2028. Strategic pivot positions company in precision oncology.

#WHWK Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company

www.stocktitan.net/news/WHWK/aadi-bioscienc...